Evidence map›Paper›PMID 36754962›Full record

ArticleNature communications2023

A subset of antibodies targeting citrullinated proteins confers protection from rheumatoid arthritis.

Yibo He, Changrong Ge, Àlex Moreno-Giró, Bingze Xu, Christian M Beusch, Katalin Sandor, Jie Su, Lei Cheng, Erik Lönnblom, Christina Lundqvist and 17 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
14.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Recent advances in autoantibody-mediated pain.Current opinion in supportive and palliative care · 2026
    Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Observational
  8. Targeting Neutrophil Function as Therapy for Hidradenitis Suppurativa.International journal of molecular sciences · 2026
    Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 5 institutions in 3 countries.

Yibo HeSection for Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77, Stockholm, Sweden.
Changrong GeSection for Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77, Stockholm, Sweden.
Àlex Moreno-GiróSection for Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-4655-1639
Bingze XuSection for Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77, Stockholm, Sweden.
Christian M BeuschDivision of Physiological Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-9100-8283
Katalin SandorDepartment of Physiology and Pharmacology, Center for Molecular Medicine, Karolinska Institutet, 17177, Stockholm, Sweden.ORCID http://orcid.org/0000-0003-3228-6907
Jie SuDivision of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-9828-9794
Lei ChengSection for Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77, Stockholm, Sweden.
Erik LönnblomSection for Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-1311-2541
Christina LundqvistDepartment of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Göteborg, Göteborg, Sweden.ORCID http://orcid.org/0000-0002-2256-4072
Linda M SlotDepartment of Rheumatology C1-R, Leiden University Medical Center, PO Box 9600, Leiden, 2300RC, The Netherlands.
Dongmei TongSection for Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77, Stockholm, Sweden.
Vilma UrbonaviciuteSection for Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77, Stockholm, Sweden.
Bibo LiangSection for Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77, Stockholm, Sweden.
Taotao LiSection for Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77, Stockholm, Sweden.
Gonzalo Fernandez LahoreSection for Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77, Stockholm, Sweden.
Mike AounSection for Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77, Stockholm, Sweden.
Vivianne MalmströmDepartment of Medicine, Division of Rheumatology, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-9251-8082
Theo RispensDepartment of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, 1066 CX, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0001-9600-1312
Patrik ErnforsDivision of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-1140-3986
Camilla I SvenssonDepartment of Physiology and Pharmacology, Center for Molecular Medicine, Karolinska Institutet, 17177, Stockholm, Sweden.
Hans Ulrich SchererDepartment of Rheumatology C1-R, Leiden University Medical Center, PO Box 9600, Leiden, 2300RC, The Netherlands.ORCID http://orcid.org/0000-0002-5700-5617
René E M ToesDepartment of Rheumatology C1-R, Leiden University Medical Center, PO Box 9600, Leiden, 2300RC, The Netherlands.ORCID http://orcid.org/0000-0002-9618-6414
Inger GjertssonDepartment of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Göteborg, Göteborg, Sweden.
Olov EkwallDepartment of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Göteborg, Göteborg, Sweden.ORCID http://orcid.org/0000-0002-4506-9955
Roman A ZubarevDivision of Physiological Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-9839-2089
Rikard HolmdahlSection for Medical Inflammation Research, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, 171 77, Stockholm, Sweden. Rikard.Holmdahl@ki.se.ORCID http://orcid.org/0000-0002-4969-2576
Karolinska Institutet · SELeiden University Medical Center · NLUniversity of Gothenburg · SEAmsterdam UMC Location University of Amsterdam · NLKarolinska University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although elevated levels of anti-citrullinated protein antibodies (ACPAs) are a hallmark of rheumatoid arthritis (RA), the in vivo functions of these antibodies remain unclear. Here, we have expressed monoclonal ACPAs derived from patients with RA, and analyzed their functions in mice, as well as their specificities. None of the ACPAs showed arthritogenicity nor induced pain-associated behavior in mice. However, one of the antibodies, clone E4, protected mice from antibody-induced arthritis. E4 showed a binding pattern restricted to skin, macrophages and dendritic cells in lymphoid tissue, and cartilage derived from mouse and human arthritic joints. Proteomic analysis confirmed that E4 strongly binds to macrophages and certain RA synovial fluid proteins such as α-enolase. The protective effect of E4 was epitope-specific and dependent on the interaction between E4-citrullinated α-enolase immune complexes with FCGR2B on macrophages, resulting in increased IL-10 secretion and reduced osteoclastogenesis. These findings suggest that a subset of ACPAs have therapeutic potential in RA.

Indexed as

Arthritis, RheumatoidAutoantibodiesAminosalicylic AcidsAnimalsHumansMicePhosphopyruvate HydrataseProteomicsacetyl 4-aminosalicylic acidAminosalicylic AcidsAutoantibodiesPhosphopyruvate Hydratase

Identifiers

PMID36754962
PMCPMC9908943
OpenAlexW4319593293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.